title: Side effects during recombinant human erythropoietin therapy in 2,000 ESRD patients.
authors.affiliation: Klinikum Grosshadern, Ludwig-Maximilians-Universität, München, FRG.
authors.forename: W
authors.initials: W
authors.lastname: Samtleben
authors.forename: B
authors.initials: B
authors.lastname: Ehmer
authors.forename: I
authors.initials: I
authors.lastname: Lutz-Knochenhauer
authors.forename: C
authors.initials: C
authors.lastname: Hagmann
authors.forename: P
authors.initials: P
authors.lastname: Scigalla
authors.forename: H J
authors.initials: HJ
authors.lastname: Gurland
mesh_terms: D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000188:drug therapy*; D001777:Blood Coagulation / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D004921:Erythropoietin / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects; D006435:Renal Dialysis; D015996:Survival Rate
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin